Status:
TERMINATED
Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib
Lead Sponsor:
Infinity Pharmaceuticals, Inc.
Collaborating Sponsors:
MedImmune LLC
AstraZeneca
Conditions:
Gastrointestinal Stromal Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
IPI-504-06 is a Phase 3, randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of IPI-504 as compared to placebo in patients with metastatic and/or unres...
Eligibility Criteria
Inclusion
- At least 18 years of age at the time of study randomization.
- Histologically confirmed metastatic and/or unresectable GIST.
- Measurable disease on CT or MRI as defined by RECIST.
- Documented radiographic progression or intolerance to imatinib and sunitinib.
- Clinical failure of the most recent prior therapy for GIST. Note: There is no limit to the number of prior therapies a patient may have received.
- Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1.
- Hemoglobin ≥ 8.0 g/dL (80 g/L).
- Absolute Neutrophil Count ≥ 1500/µL (1.5 x 109/L).
- Platelets ≥ 100,000 /µL (100 x 109/L).
- ALT and AST ≤ 2.5 x upper limit of normal (ULN), or ≤ 5.0 x ULN if considered secondary to liver metastases.
- Alkaline phosphatase ≤ 2.5 x ULN, or ≤ 5.0 x ULN if considered secondary to liver metastases.
- Serum bilirubin ≤ 1.5 x ULN.
- PT and PTT ≤ 1.5 x ULN unless the patient is receiving warfarin. If the patient is receiving warfarin, the INR must be within therapeutic range.
- Serum creatinine ≤ 1.5 x ULN.
Exclusion
- Previous administration of other known heat shock protein 90 (Hsp90) inhibitors.
- Surgery, radiotherapy, or lesion ablative procedure to the only area of measurable disease.
- Initiation or discontinuation of concurrent medication that is a potent CYP3A inhibitor less than 2 weeks prior to administration of IPI-504 or placebo.
- History of any of the following within the last 6 months: cardiac disease such as acute coronary syndrome or unstable angina, symptomatic congestive heart failure, uncontrolled hypertension, cirrhotic liver disease, cerebrovascular accident, or any other significant co-morbid condition or disease which, in the judgment of the investigator, would place the patient at undue risk or interfere with the study.
- Grade 3 or 4 hemorrhagic event within the last 6 months.
- Known human immunodeficiency virus positivity.
- Sinus bradycardia (resting heart rate \< 50 bpm) secondary to intrinsic conduction system disease.
- QTcF ≥ 470 milliseconds, or previous history of clinically significant QTc prolongation while taking other medications.
- History of prior malignancies within the past 3 years other than non-melanomatous skin cancers that have been controlled, prostate cancer that has been treated and has not recurred, non-muscle-invasive bladder cancer, and carcinoma in situ of the cervix.
- Active or recent history (within 3 months) of keratitis or keratoconjunctivitis confirmed by ophthalmology or optometry exam.
- Presence of Left Bundle Branch Block, Right Bundle Branch Block plus left anterior hemiblock, bifascicular block, or 3rd degree heart block. This does not include patients with a history of these events with adequate control by pacemaker.
- Known CNS metastases.
- Women who are pregnant or lactating.
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT00688766
Start Date
August 1 2008
End Date
May 1 2009
Last Update
December 11 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.